MiniMed Reports Strong Growth as New Pump Line Gains Traction
MiniMed (NASDAQ:MMED) reported robust financial results for its first full quarter as an independent public company, with revenue rising 15.8% to $843 million and management raising its annual growth outlook. The surge was driven by the successful launch of the Flex insulin pump in late June, which has attracted both new patients and users switching from competitors. In the US market alone, new pump sales increased over 20%, while international revenue grew 16.9% due to improved sensor production and demand fulfillment. MiniMed is also making progress with its product pipeline, including an early filing for a Fit patch pump and positive trial results for Vivera, a closed-loop algorithm that showed strong performance in managing Type 1 diabetes without manual input. However, the company faced margin pressures from separation costs, accelerated spending on new products, currency charges, and lower-margin sensor sales. Despite these challenges, investor interest is growing, with hedge fund ownership increasing to 26 funds. While short-term growth may normalize next quarter due to calendar effects, MiniMed's long-term momentum appears strong as it continues transitioning from Medtronic.
Topics: Diabetes Management Market Expansion Medical Devices Revenue Growth